Molecular recognition-driven supramolecular nanoassembly of a hydrophobic uracil prodrug and hydrophilic cytarabine for exact mixture therapy of stable and non-solid tumors

Mixture chemotherapy has proven distinct therapeutic benefits over monotherapy in scientific most cancers therapy, particularly for 2 chemotherapeutic medication with totally different mechanisms of motion. Nevertheless, how one can obtain environment friendly co-delivery of two or extra medication with totally different physicochemical and pharmacokinetic properties for synergistic remedy continues to be an enormous problem. Specifically, it’s much more troublesome to effectively co-deliver a hydrophilic drug and a hydrophobic drug into one nanosystem. Herein, impressed by the pure Watson–Crick base pair molecular recognition in nucleic acids, a reduction-sensitive uracil prodrug of doxorubicin (U-SS-DOX) is synthesized and performs supramolecular co-assembly with cytarabine (Ara-C). Apparently, the hydrophilic Ara-C molecules might readily co-assemble with U-SS-DOX, and a number of hydrogen bonds are discovered within the nanoassembly with an ultra-high drug loading price. Furthermore, 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine iodide (DiR) is used as a fluorescent probe to research the pharmacokinetics of U : C NPs. It seems that the DiR-labeled U : C NPs considerably delay the systemic circulation and promote the tumor-specific accumulation of DiR compared with DiR resolution. Moreover, the supramolecular nanoassembly demonstrates potent passable therapeutic results in treating each stable and non-solid tumors in vivo. This research gives a novel molecular co-assembly nanoplatform for environment friendly co-delivery of hydrophilic and hydrophobic medication.